ReviewMediators of inflammation2014
Trypanosoma cruzi infection and host lipid metabolism.
Review in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Ginkgo biloba attenuated detrimental inflammatory and oxidative events due to Trypanosoma brucei rhodesiense in mice treated with melarsoprol.PLoS neglected tropical diseases · 2024Article
- Genomic evidence of sex chromosome aneuploidy and infection-associated genotypes in the tsetse fly Glossina fuscipes, the major vector of African trypanosomiasis in Uganda.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2023Article
- Coenzyme QJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- Very low HDL levels: clinical assessment and management.Archives of endocrinology and metabolism · 2023Review
- Blimp-1 signaling pathways in T lymphocytes is essential to control theFrontiers in immunology · 2023Article
- Down-Regulation of Lipid Metabolism in the Hepatopancreas of ShrimpInternational journal of molecular sciences · 2022Article
- Modulation of Macrophage Immunometabolism: A New Approach to Fight Infections.Frontiers in immunology · 2022Review
- The Liver and the Hepatic Immune Response inPathogens (Basel, Switzerland) · 2021Review
- Clinical and epidemiological aspects of chronic Chagas disease from Southern Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
- ACAT-1 gene rs1044925 SNP and its relation with different clinical forms of chronic Chagas disease.Parasitology research · 2019Article
- Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole.Open forum infectious diseases · 2018Article
- Leptin Functions in Infectious Diseases.Frontiers in immunology · 2018Review
- Antagonistic effect of atorvastatin on high fat diet induced survival during acute Chagas disease.Microbes and infection · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trypanosoma cruzi is the causative agent of Chagas disease. Approximately 8 million people are thought to be affected worldwide. Several players in host lipid metabolism have been implicated in T. cruzi-host interactions in recent research, including macrophages, adipocytes, low density lipoprotein (LDL), low density lipoprotein receptor (LDLR), and high density lipoprotein (HDL). All of these factors are required to maintain host lipid homeostasis and are intricately connected via several metabolic pathways. We reviewed the interaction of T. cruzi with each of the relevant host components, in order to further understand the roles of host lipid metabolism in T. cruzi infection. This review sheds light on the potential impact of T. cruzi infection on the status of host lipid homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.